KRKG Stock Overview
Develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €165.00 |
| 52 Week High | €167.00 |
| 52 Week Low | €117.00 |
| Beta | 0.53 |
| 1 Month Change | 17.86% |
| 3 Month Change | 21.32% |
| 1 Year Change | 40.43% |
| 3 Year Change | 44.10% |
| 5 Year Change | 114.29% |
| Change since IPO | 1,980.32% |
Recent News & Updates
Is Krka, d. d. (LJSE:KRKG) Trading At A 32% Discount?
Jan 14
Krka, d. d.'s (LJSE:KRKG) Share Price Could Signal Some Risk
Dec 13Krka, d. d.'s (LJSE:KRKG) Shareholders Might Be Looking For Exit
Aug 27Recent updates
Is Krka, d. d. (LJSE:KRKG) Trading At A 32% Discount?
Jan 14Krka, d. d.'s (LJSE:KRKG) Share Price Could Signal Some Risk
Dec 13Krka, d. d.'s (LJSE:KRKG) Shareholders Might Be Looking For Exit
Aug 27Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?
Aug 09Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year
Jul 22Krka d. d (LJSE:KRKG) Will Pay A Larger Dividend Than Last Year At €7.50
Jun 11Shareholder Returns
| KRKG | SI Pharmaceuticals | SI Market | |
|---|---|---|---|
| 7D | 2.5% | 2.0% | 3.2% |
| 1Y | 40.4% | 0.6% | 39.2% |
Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned 0.6% over the past year.
Return vs Market: KRKG exceeded the SI Market which returned 39.2% over the past year.
Price Volatility
| KRKG volatility | |
|---|---|
| KRKG Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 2.6% |
| 10% most volatile stocks in SI Market | 4.8% |
| 10% least volatile stocks in SI Market | 1.9% |
Stable Share Price: KRKG has not had significant price volatility in the past 3 months compared to the SI market.
Volatility Over Time: KRKG's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 11,745 | Jože Colaric | www.krka.biz |
Krka, d. d. develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for cardiovascular, central nervous system, gastrointestinal tract, pain relief, diabetes, blood and blood-forming organs, anti-infectives for systemic use, oncology, and other applications. The company also provides non-prescription products, such as cough and cold products, pain relief, vitamins and minerals, gastrointestinal tract and metabolism, and peripheral vasodilators.
Krka, d. d. Fundamentals Summary
| KRKG fundamental statistics | |
|---|---|
| Market cap | €5.07b |
| Earnings (TTM) | €359.83m |
| Revenue (TTM) | €1.90b |
14.1x
P/E Ratio2.7x
P/S RatioIs KRKG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRKG income statement (TTM) | |
|---|---|
| Revenue | €1.90b |
| Cost of Revenue | €825.70m |
| Gross Profit | €1.07b |
| Other Expenses | €714.99m |
| Earnings | €359.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 10, 2025
| Earnings per share (EPS) | 11.70 |
| Gross Margin | 56.55% |
| Net Profit Margin | 18.93% |
| Debt/Equity Ratio | 0% |
How did KRKG perform over the long term?
See historical performance and comparisonDividends
4.5%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 23:42 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krka, d. d. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saso Stanovnik | Alta Invest |
| Simon Mather | Barclays |
| Stephane Sumar | BNP Paribas Exane |